BiVictriX Therapeutics PLC Appointment of Adrian Howd as CFO and CBO (4416O)
October 03 2023 - 1:00AM
UK Regulatory
TIDMBVX
RNS Number : 4416O
BiVictriX Therapeutics PLC
03 October 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Appointment of Adrian Howd as Chief Financial Officer
and Chief Business Officer
Alderley Park, 03 October 2023 - BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a
differentiated approach to develop novel, next-generation
anti-cancer precision Antibody Drug Conjugates, offering
substantially improved cancer cell selectivity and therapeutic
activity, today announces that it has appointed Adrian Howd, PhD as
combined Chief Financial Officer ("CFO") and Chief Business Officer
("CBO"). Alex Hughes will be stepping down from his position as CFO
on 13 October.
Adrian joins BiVictriX with over 20 years of strategic financial
and commercial experience in the biopharmaceutical industry, having
held various financial roles, private and public executive
management positions and board roles across the sector. During his
career to date he has led multiple asset and corporate business
development transactions, as well as numerous equity capital market
fundraises totalling over EUR430 million. Adrian possesses
substantial equity capital markets experience in the UK and
overseas, gained during his previous senior roles at Berenberg
Bank, ABN Amro and Nomura.
Adrian has also held various senior management roles, including
Chief Investment Officer and Chief Executive Officer at investment
firm, Malin plc, where he led the Company to its debut on the Irish
Stock Exchange in one of the largest European life science initial
public offerings to date.
At Malin, Adrian led investments in and served on the boards of
both Immunocore and Kymab, two "platform to therapeutic" UK-based
companies, both of which achieved multibillion USD exits via a
NASDAQ IPO and a trade sale to Sanofi respectively.
Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics
plc, added: "We are delighted to welcome Adrian as Chief Financial
Officer and Chief Business Officer. His substantial financial
acumen, combined with his strong track record of strategic and
operational success with UK oncology businesses will be invaluable,
as we look to secure partnership deals and accelerate BiVictriX
towards our next phase of development. On behalf of the entire
team, I would like to express my thanks to Alex for his
contributions to the Company and wish him all the best in his
future endeavours."
Adrian Howd, newly appointed Chief Financial Officer and Chief
Business Officer of BiVictriX Therapeutics plc, said: "BiVictriX
Therapeutics has reached a critical inflection point, having
achieved compelling and differentiated pre-clinical data for its
lead asset as well as broadening the technology pipeline and
building the foundations of a robust, patent-protected portfolio. I
strongly believe in the potential of the Bi-Cygni(R) Platform to
revolutionise cancer therapy and the Company has multiple strategic
options, for its lead asset and also in the wider solid tumour
space. At this point in the Company's evolution, I see parallels
between other companies I have successfully worked with in the
oncology space and I am looking forward to joining Tiffany and the
wider BiVictriX team to maximise shareholder value from the
science."
ENDS
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Email: info@bivictrix.com
Chairman
SP Angel Corporate Finance LLP Tel: +44 (0) 20 3470 0470
(NOMAD and Broker)
David Hignell, Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre, Rob Rees (Sales
and Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886 2500
Broker)
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR Consilium
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Max Bennett, Emmalee Hoppe Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a new
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst significantly reducing
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) Antibody Drug Conjugate
therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "Bi-Cygni(R) fingerprints", on
tumour cells, which are largely absent from healthy cells.
BiVictriX has established a growing proprietary library of
cancer-specific Bi-Cygni(R) fingerprints, which enable the Company
to target a diverse array of different cancer types. The Company
utilises these novel Bi-Cygni(R) fingerprints, together with the
Company's novel Antibody Drug Conjugate therapeutic design, to
develop more effective and safer therapeutics to target cancers
that are expected to constitute orphan indications and areas of
high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUUOBROWURRAA
(END) Dow Jones Newswires
October 03, 2023 02:00 ET (06:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Sep 2023 to Sep 2024